EU OKs $22B Bioscience Cos. Merger After Remedies
Europe's competition regulator cleared the approximately $22 billion combination of Danish biosciences companies Novozymes A/S and Chr. Hansen Holding A/S, guided by five law firms, after agreeing to divest a slice...To view the full article, register now.
Already a subscriber? Click here to view full article